Literature DB >> 16328530

Sporadic four-repeat tauopathy with frontotemporal degeneration, parkinsonism and motor neuron disease.

Yue-Shan Piao1, Chun-Feng Tan, Keisuke Iwanaga, Akiyoshi Kakita, Hiroki Takano, Masatoyo Nishizawa, Tammaryn Lashley, Tamas Revesz, Andrew Lees, Rohan de Silva, Mitsuhiro Tsujihata, Hitoshi Takahashi.   

Abstract

We report a sporadic tauopathy of 6-year duration in a 76-year-old woman. Her initial symptoms were asymmetrical parkinsonism and muscle weakness, with apraxia appearing 2 years later. The brain showed frontal and temporal cerebral atrophy; severe neuronal loss and gliosis were observed in the precentral cortex (loss of Betz cells was also evident) and premotor area, and in the medial temporal lobe, including the temporal tip, amygdala, and hippocampal CA1-subiculum border zone. The substantia nigra showed moderate neuronal loss and gliosis. In the spinal cord, loss of the anterior horn cells and degeneration of the corticospinal tracts were a characteristic feature. In addition, in the affected regions, the remaining neurons were often found to contain intracytoplasmic inclusions resembling neurofibrillary tangles. Tau immunostaining revealed widespread glial-predominant lesions in the cerebral gray and white matter. In contrast, predominance of neuronal lesions (pretangles/tangles) was a feature in the subcortical gray matter, including the spinal cord. The remaining upper and lower motor neurons were also affected by tau pathology. Accumulated tau in these glial cells and neurons was clearly recognized by a specific antibody against four-repeat (4R) tau. The ultrastructural presence of tau-positive tubular structures was confirmed in the glial cells and neurons (tangles). Immunoblotting of a frozen frontal lobe sample revealed accumulation of 4R-predominant tau isoforms. No mutations were found in the tau gene. These findings indicate that a sporadic 4R tauopathy can cause frontotemporal degeneration, parkinsonism, and motor neuron disease. The present case could represent a new clinicopathological phenotype of non-familial tauopathy.

Entities:  

Mesh:

Year:  2005        PMID: 16328530     DOI: 10.1007/s00401-005-1086-5

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  10 in total

1.  Globular glial tauopathies (GGT): consensus recommendations.

Authors:  Zeshan Ahmed; Gabor G Kovacs; Eileen H Bigio; Herbert Budka; Dennis W Dickson; Isidro Ferrer; Bernardino Ghetti; Giorgio Giaccone; Kimmo J Hatanpaa; Janice L Holton; Keith A Josephs; James Powers; Salvatore Spina; Hitoshi Takahashi; Charles L White; Tamas Revesz
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

2.  A novel tau mutation, p.K317N, causes globular glial tauopathy.

Authors:  Pawel Tacik; Michael DeTure; Wen-Lang Lin; Monica Sanchez Contreras; Aleksandra Wojtas; Kelly M Hinkle; Shinsuke Fujioka; Matthew C Baker; Ronald L Walton; Yari Carlomagno; Patricia H Brown; Audrey J Strongosky; Naomi Kouri; Melissa E Murray; Leonard Petrucelli; Keith A Josephs; Rosa Rademakers; Owen A Ross; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2015-04-22       Impact factor: 17.088

3.  Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings.

Authors:  M E Erro; M V Zelaya; M Mendioroz; R Larumbe; S Ortega-Cubero; J L Lanciego; A Lladó; T Cabada; T Tuñón; F García-Bragado; M R Luquin; P Pastor; I Ferrer
Journal:  J Neurol       Date:  2019-06-12       Impact factor: 4.849

4.  Atypical Alzheimer's disease in an elderly United States resident with amyotrophic lateral sclerosis and pathological tau in spinal motor neurons.

Authors:  Leo F McCluskey; Felix Geser; Lauren B Elman; Vivianna M Van Deerlin; John L Robinson; Virginia M-Y Lee; John Q Trojanowski
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-05-09       Impact factor: 4.092

5.  Progressive supranuclear palsy and primary lateral sclerosis secondary to globular glial tauopathy: a case report and a practical theoretical framework for the clinical prediction of this rare pathological entity.

Authors:  Andy J Liu; Jessica E Chang; Georges Naasan; Adam L Boxer; Bruce L Miller; Salvatore Spina
Journal:  Neurocase       Date:  2020-02-23       Impact factor: 0.881

6.  White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration.

Authors:  Gabor G Kovacs; Katalin Majtenyi; Salvatore Spina; Jill R Murrell; Ellen Gelpi; Romana Hoftberger; Graham Fraser; R Anthony Crowther; Michel Goedert; Herbert Budka; Bernardino Ghetti
Journal:  J Neuropathol Exp Neurol       Date:  2008-10       Impact factor: 3.685

7.  Extensive deamidation at asparagine residue 279 accounts for weak immunoreactivity of tau with RD4 antibody in Alzheimer's disease brain.

Authors:  Ayaho Dan; Muneaki Takahashi; Masami Masuda-Suzukake; Fuyuki Kametani; Takashi Nonaka; Hiromi Kondo; Haruhiko Akiyama; Takao Arai; David M A Mann; Yuko Saito; Hiroyuki Hatsuta; Shigeo Murayama; Masato Hasegawa
Journal:  Acta Neuropathol Commun       Date:  2013-08-21       Impact factor: 7.801

8.  Expanding the phenotypic associations of globular glial tau subtypes.

Authors:  James R Burrell; Shelley Forrest; Thomas H Bak; John R Hodges; Glenda M Halliday; Jillian J Kril
Journal:  Alzheimers Dement (Amst)       Date:  2016-04-08

9.  Involvement of Oligodendrocytes in Tau Seeding and Spreading in Tauopathies.

Authors:  Isidro Ferrer; Meritxell Aguiló García; Margarita Carmona; Pol Andrés-Benito; Benjamin Torrejón-Escribano; Paula Garcia-Esparcia; José Antonio Del Rio
Journal:  Front Aging Neurosci       Date:  2019-05-28       Impact factor: 5.750

10.  Factors associated with development and distribution of granular/fuzzy astrocytes in neurodegenerative diseases.

Authors:  Tomoko Miki; Osamu Yokota; Takashi Haraguchi; Hideki Ishizu; Masato Hasegawa; Takeshi Ishihara; Shu-Ichi Ueno; Shintaro Takenoshita; Seishi Terada; Norihito Yamada
Journal:  Brain Pathol       Date:  2020-05-06       Impact factor: 6.508

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.